Indian biopharmaceutical company Biocon Ltd disclosed that its active pharmaceutical ingredient (API) manufacturing site in Visakhapatnam, Andhra Pradesh, was issued two observations following a routine US Food and Drug Administration (FDA) inspection. The surveillance visit, conducted between 3 and 7 November 2025, concluded with authorities noting two matters requiring correction in the Form 483 inspection report.

Biocon confirmed in a regulatory filing that it does not expect the observations to have any material impact on its business operations. The company is now preparing its formal response and taking steps to address the issues within the regulatory timeline.

The Visakhapatnam operation forms a key part of Biocon’s global API supply chain, serving both regulated and emerging markets. The company emphasised its ongoing commitment to maintaining compliance with current good manufacturing practices (cGMP) and continuous improvement across its manufacturing network.